Published online Aug 27, 2024. doi: 10.4240/wjgs.v16.i8.2365
Revised: May 20, 2024
Accepted: June 5, 2024
Published online: August 27, 2024
Processing time: 160 Days and 17.7 Hours
Patients with metastatic gastric cancer have a grim prognosis. Palliative che
Core Tip: The prognosis of patients with gastric cancer and liver metastasis is abysmal. Palliative chemotherapy is associated with a limited survival benefit yet is very toxic. Immunotherapy is considered an emerging promising therapy with some remarkable results. There has been a growing body of literature from animal and human studies that question the efficacy of immunotherapy in these patients. In this article, we discuss this issue and provide a balanced appraisal of the literature.
- Citation: Dehal A. Immunotherapy for gastric cancer and liver metastasis: Is it time to bid farewell. World J Gastrointest Surg 2024; 16(8): 2365-2368
- URL: https://www.wjgnet.com/1948-9366/full/v16/i8/2365.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i8.2365
The median survival of patients with metastatic gastric cancer is only 3 to 5 months without treatment. Palliative chemotherapy may prolong survival to approximately 9-11 months in patients with Her2-negative disease[1]. Recently, immunotherapy has emerged as a promising therapy after a remarkable response in various malignancies. Results from several randomized trials, including the Checkmate-649[2] trial and the KEYNOTE-158[3] trial, which showed improved survival compared to chemotherapy, led to the approval of drugs such as Nivolumab and Pembrolizumab, respectively.
Current recommendations for the management of patients with HER2-negative metastatic gastric cancer include Fluoropyrimidine, oxaliplatin, or Cisplatin, with or without nivolumab or pembrolizumab as first-line therapy, followed by Ramucirumab and paclitaxel, Docetaxel, Paclitaxel, Irinotecan, Fluorouracil, or irinotecan as a second line therapy[4]. However, several pre-clinical[5] and clinical studies[6-8] have suggested reduced efficacy of immunotherapy in patients with liver metastases in melanoma and non-small cell lung cancer. Scientific observation from animal studies nicely described the mechanisms for this phenomenon. Liver metastases induce a systemic loss of antigen-specific T cells, siphon activated CD8+ T cells from the systemic circulation, reduce peripheral T cell numbers, and diminish tumoral T cell diversity and function. Liver metastases alter the hepatic immune microenvironment by inducing activated T cell apoptosis via the Fas-FasL pathway. Consequently, liver metastases create a systemic immune desert[5].
In gastric cancer, previous studies evaluating the efficacy of immunotherapy in the setting of liver metastases have shown conflicting results. In a subgroup analysis with a 2-year follow-up from the CheckMate-649, the presence of liver metastases did not impact the rate of response in patients with metastatic gastric cancer treated with immunotherapy[9]. Similarly, findings from the ATTRACTION-2 trial and the ATTRACTION-4 trial demonstrated that the survival benefit of Nivolumab did exist regardless of the status of the liver metastases[10,11]. Contrarily, in the REGONIVO trial, patients with liver metastases had a response rate of approximately 42%, whereas patients without liver involvement had a response rate of 80%[12]. Retrospective studies examining the role of immunotherapy in patients with gastric cancer and liver metastases have yielded mixed results as well. Some studies demonstrated that liver metastasis was associated with a decreased response rate and rapid disease progression, compared to other metastases[13,14], whereas other studies showed no such impact[15].
In the study by Liu et al[16] published in this issue of the World Journal of Gastrointestinal Surgery, the authors challenged the efficacy of immunotherapy in this group of patients. This study is a small (n = 48) retrospective evaluation of patients with HER2-negative metastatic gastric cancer treated with immunotherapy at a Chinese hospital. The methodology is a simple comparison of two groups of patients (metastatic gastric cancer with or without liver metastasis) across the study outcomes: Objective response rate, disease control rate, progression-free survival (PFS), and overall survival. Although clinical differences were noted between the two groups in all measured outcomes favoring the group without liver metastasis, apart from the PFS, none of the other outcomes showed statistical significance. The study concluded that immunotherapy is less effective in patients with liver metastases than those without.
I commend the authors for their efforts to expand our understanding of the role of immunotherapy for this disease and improve patient selection for this costly and potentially risky treatment. Several issues are worth discussing. Paclitaxel is not a first-line chemotherapy for patients with metastatic gastric cancer. Tirellizumab, an investigational, humanized PD-1 inhibitor, has demonstrated preliminary antitumor activity in hepatocellular carcinoma. It is unclear how this agent was selected as part of the combination regimen as it has not been approved for treating metastatic gastric cancer patients. The study's retrospective design, with its inherited selection bias, especially given the significant difference in baseline performance status and, finally, the small sample size, are additional issues that should be considered when evaluating the study.
While some studies suggest a limited efficacy of immunotherapy in patients with gastric cancer and liver metastases, a broader examination of the literature revealed diverse findings. Other studies counter this notion, demonstrating that the mere presence of liver metastases does not definitively predict poor response to immunotherapy; instead, it underscores the importance of delving into the underlying tumor biology as variation in molecular characteristics and genetic makeup may play a pivotal role in determining the responsiveness of these patients.
Throughout history, surgeons have always understood with much clarity that the biology of the tumor dictates prognosis. No better than the late Dr. Blake Clady's famous quotation, "Biology is King," who eloquently illustrated this understanding. However, as another surgical giant, the late Dean Lutin, once said, "We are only at the foothills of understanding cancer, and the biological mountain still lies in the clouds ahead," we are yet to fully understand the biology of tumors. The diverse response to immunotherapy in patients with gastric cancer and liver metastases may be attributed to several underlying tumor biological characteristics such as a tumor microenvironment, immune cell infiltration, and expression of immune checkpoint. Tumors with high levels of immune cell infiltration and increased expression of PD L1 may exhibit an enhanced response to immunotherapy[17].
Additionally, genomic instability, tumor mutational burden, and specific molecular subtypes of gastric cancer can influence treatment outcomes[18-20]. Even more interesting is the revolutionary cutting-edge single-cell omics and spatial transcriptomics technologies, which enabled the exploration of cellular heterogeneity and molecular landscapes of gastric cancer at the single-cell level and revolutionized our understanding of cellular function and tissue organization. These technologies have a promising potential for even more personalized treatment for patients with gastric cancer[21-23]. Therefore, it is not time yet to bid farewell to immunotherapy in this unfortunate group of patients whose prognosis is otherwise dismal. Instead, we need to shift focus toward comprehensive tumor profiling to identify these biomarkers and understand the molecular intricacies of individual cases to tailor more personalized and effective treatment strategies.
1. | Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1579] [Cited by in F6Publishing: 1639] [Article Influence: 102.4] [Reference Citation Analysis (0)] |
2. | Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1201] [Cited by in F6Publishing: 1368] [Article Influence: 456.0] [Reference Citation Analysis (0)] |
3. | Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1-10. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 942] [Cited by in F6Publishing: 1652] [Article Influence: 330.4] [Reference Citation Analysis (0)] |
4. | Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167-192. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 41] [Cited by in F6Publishing: 607] [Article Influence: 303.5] [Reference Citation Analysis (0)] |
5. | Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152-164. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 234] [Cited by in F6Publishing: 486] [Article Influence: 162.0] [Reference Citation Analysis (0)] |
6. | Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open. 2021;4:e2118416. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 66] [Article Influence: 22.0] [Reference Citation Analysis (0)] |
7. | Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X, Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020;10:546604. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis (0)] |
8. | Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017;5:417-424. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 263] [Cited by in F6Publishing: 393] [Article Influence: 56.1] [Reference Citation Analysis (0)] |
9. | Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Amaya Chanaga C, Soleymani S, Liu T. P-86 First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up. Ann Oncol. 2022;33:S279. [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
10. | Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461-2471. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1283] [Cited by in F6Publishing: 1565] [Article Influence: 223.6] [Reference Citation Analysis (0)] |
11. | Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234-247. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 60] [Article Influence: 30.0] [Reference Citation Analysis (0)] |
12. | Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38:2053-2061. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 234] [Cited by in F6Publishing: 434] [Article Influence: 108.5] [Reference Citation Analysis (0)] |
13. | Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22:793-802. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 93] [Cited by in F6Publishing: 111] [Article Influence: 22.2] [Reference Citation Analysis (0)] |
14. | Topp BG, Thiagarajan K, De Alwis DP, Snyder A, Hellmann MD. Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. Ann Oncol. 2021;32:1618-1625. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
15. | Lin GT, Liu ZY, Shang-Guan ZX, Zeng GR, Lin JX, Wu J, Chen QY, Xie JW, Li P, Huang CM, Zheng CH. Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real-world retrospective study. Cancer Med. 2023;12:12221-12233. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
16. | Liu K, Wu CX, Liang H, Wang T, Zhang JY, Wang XT. Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis. World J Gastrointest Surg. 2024;16:700-709. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
17. | Ferrata M, Schad A, Zimmer S, Musholt TJ, Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM, Fottner C. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. Front Oncol. 2019;9:343. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis (0)] |
18. | Lazăr DC, Avram MF, Romoșan I, Cornianu M, Tăban S, Goldiș A. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. World J Gastroenterol. 2018;24:3583-3616. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 97] [Article Influence: 16.2] [Reference Citation Analysis (0)] |
19. | Kim TS, da Silva E, Coit DG, Tang LH. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. Am J Surg Pathol. 2019;43:851-860. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis (0)] |
20. | Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, Zhang Z, Lu L, Zhang X. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol. 2022;13:862084. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
21. | Ren L, Huang D, Liu H, Ning L, Cai P, Yu X, Zhang Y, Luo N, Lin H, Su J, Zhang Y. Applications of single‑cell omics and spatial transcriptomics technologies in gastric cancer (Review). Oncol Lett. 2024;27:152. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
22. | Li X, Sun Z, Peng G, Xiao Y, Guo J, Wu B, Li X, Zhou W, Li J, Li Z, Bai C, Zhao L, Han Q, Zhao RC, Wang X. Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics. 2022;12:620-638. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 124] [Article Influence: 62.0] [Reference Citation Analysis (1)] |
23. | Hong Z, Xie W, Zhuo H, Wei X, Wang K, Cheng J, Lin L, Hou J, Chen X, Cai J. Crosstalk between Cancer Cells and Cancer-Associated Fibroblasts Mediated by TGF-β1-IGFBP7 Signaling Promotes the Progression of Infiltrative Gastric Cancer. Cancers (Basel). 2023;15. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |